INLB (Item 9 Labs) YoY EBITDA Growth: 28.57% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INLB Item 9 Labs Corp INLB
12 GF Score
Price $0.00
View Full Analysis

What is Item 9 Labs YoY EBITDA Growth?

Item 9 Labs INLB -99.00% 12 YoY EBITDA Growth is 28.57% as of Jun. 2023. GuruFocus rates INLB with a GF Score™ of 12/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Item 9 Labs's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was 28.57%.

Item 9 Labs's EBITDA per Share for the three months ended in Jun. 2023 was $-0.03.

Item 9 Labs YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Item 9 Labs's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Item 9 Labs YoY EBITDA Growth Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22,500.00 35.27 50.34 23.61 -334.55

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,400.00 -235.42 44.44 66.67 28.57
INLB
12GF Score
Item 9 Labs Corp INLB
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Item 9 Labs YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Item 9 Labs's YoY EBITDA Growth for the fiscal year that ended in Sep. 2022 is calculated as:

YoY EBITDA Growth (A: Sep. 2022 )
=(EBITDA per Share (A: Sep. 2022 )-EBITDA per Share (A: Sep. 2021 ))/ | EBITDA per Share (A: Sep. 2021 ) |
=(-0.239--0.055)/ | -0.055 |
=-334.55 %

Item 9 Labs's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (Q: Jun. 2023 )
=(EBITDA per Share (Q: Jun. 2023 )-EBITDA per Share (Q: Jun. 2022 )) / | EBITDA per Share (Q: Jun. 2022 )) |
=(-0.025--0.035)/ | -0.035 |
=28.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 28.57% mean?
Item 9 Labs (INLB) has a YoY EBITDA Growth of 28.57% as of Jun. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Item 9 Labs and its competitors.
Is Item 9 Labs' YoY EBITDA Growth too high?
Item 9 Labs' current YoY EBITDA Growth is 28.57%. Overall, Item 9 Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Item 9 Labs' YoY EBITDA Growth compare to NEPT and CENBF?
Item 9 Labs' YoY EBITDA Growth of 28.57% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Item 9 Labs and its competitors. Item 9 Labs's current YoY EBITDA Growth is 28.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Item 9 Labs stock overvalued right now?
Item 9 Labs (INLB) has a current YoY EBITDA Growth of 28.57%. The current YoY EBITDA Growth is 28.57%. Item 9 Labs' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Item 9 Labs (INLB), the current YoY EBITDA Growth is 28.57% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Item 9 Labs Business Description

Address 2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
12GF Score

Get the complete analysis for INLB

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price